Pharmaceuticals & Drugs
|Market Cap||39,724 Cr||EPS||12.1||High||404|
|Stock P/E||32.4||Net Profit Margin||12.2||Low||392.4|
|Market Cap||39,724 Cr||ROE||15.5%|
|P/B Ratio||3.1||Dividend Yield||0.6%|
|Industry P/E||63.6||Book Value||127.3|
About the Company
Cadila Healthcare Limited, a company limited by shares, incorporated and domiciled in India, operates as an integrated pharmaceutical company with business encompassing the entire value chain in the research, development, production, marketing and distribution of pharmaceutical products. The product portfolio of the company includes Active Pharmaceutical Ingredients (API) and human formulations. The company’s shares are listed on the National Stock Exchange of India Limited (NSE) and BSE Limited.
The company’s initiatives in the areas of research and development span across the pharmaceuticals value chain, including New Chemical Entities (NCE), biologics, vaccines, specialty and complex generic formulations and API process development. The company has a global presence and sells its products in the United States, India, Europe and emerging markets including countries in Latin America, Asia Pacific region and Africa. The company has a pool of modern, cost efficient and regulatory compliant manufacturing facilities which ensures continuous supply of high quality products at the most competitive prices to its customers across the globe.
Business area of the company
The company is one of the leading innovation driven pharmaceutical companies in India with presence across the pharmaceutical value chain of innovating (research & development), manufacturing, marketing and selling of finished dosage human formulations (generics, branded generics and specialty formulations, including biosimilars and vaccines), active pharmaceutical ingredients (APIs), animal healthcare products and consumer wellness products. Innovation is the backbone of the company as it ensures business sustainability through continuous availability of new products for various businesses.
Business verticals / products
|Parent Organisation||Zydus Lifesciences Ltd.||Managing Director||Sharvil P Patel|
All values are in Rs Cr
|Company||52 Week||Market Price||P/E Ratio|
Frequently asked questions